<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Azithromycin - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Azithromycin</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Azithromycin</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Azithromycin 250mg Tablets</li>
          <li>Azithromycin 500mg Intravenous</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Community-acquired pneumonia (outpatient)</strong>
            <ul>
              <li>PO: 500 mg on day 1, then 250 mg PO once daily on days 2–5 (total 5 days)</li>
              <li>Alternative (if severe or unable to take PO initially): 500 mg IV once daily for at least 2 days, then 500 mg PO once daily to complete 7–10 days</li>
            </ul>
          </li>
          <li><strong>Acute bacterial sinusitis (when antibiotics indicated)</strong>
            <ul>
              <li>500 mg PO once daily for 3 days</li>
            </ul>
          </li>
          <li><strong>Acute exacerbation of chronic bronchitis</strong>
            <ul>
              <li>500 mg PO on day 1, then 250 mg PO once daily on days 2–5</li>
            </ul>
          </li>
          <li><strong>Streptococcal pharyngitis (alternative to penicillin if allergic)</strong>
            <ul>
              <li>500 mg PO once daily for 3 days OR 500 mg PO on day 1, then 250 mg once daily on days 2–5</li>
            </ul>
          </li>
          <li><strong>Skin and soft tissue infections (uncomplicated)</strong>
            <ul>
              <li>500 mg PO on day 1, then 250 mg PO once daily on days 2–5</li>
            </ul>
          </li>
          <li><strong>Traveler's diarrhea (selected cases)</strong>
            <ul>
              <li>1000 mg PO as a single dose (or per local protocol)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Community-acquired pneumonia (mild-moderate)</li>
          <li>Acute bacterial sinusitis, acute bronchitis exacerbations</li>
          <li>Pharyngitis/tonsillitis (alternative to penicillin)</li>
          <li>Skin and soft tissue infections caused by susceptible organisms</li>
          <li>Selected sexually transmitted infections (per infectious disease guidelines)</li>
          <li>Atypical infections (Mycoplasma, Chlamydia, Legionella)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to azithromycin or other macrolide antibiotics (erythromycin, clarithromycin)</li>
          <li>History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use</li>
          <li>QT prolongation risk: caution in patients with known prolonged QT interval, uncorrected electrolyte abnormalities (hypokalemia, hypomagnesemia), or concurrent QT-prolonging drugs</li>
          <li>Cardiovascular disease: increased risk of cardiovascular death reported in some populations; use with caution</li>
          <li>Myasthenia gravis: exacerbation possible</li>
          <li>C. difficile-associated diarrhea risk with any antibiotic use</li>
          <li>Dose adjustment generally not required for renal impairment but use caution in severe hepatic impairment</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI upset (nausea, diarrhea, abdominal pain) – common</li>
          <li>Headache</li>
          <li>QT prolongation and risk of torsades de pointes (rare but serious)</li>
          <li>Hepatotoxicity (rare; monitor for jaundice, severe abdominal pain)</li>
          <li>Hypersensitivity reactions (rash, angioedema, anaphylaxis)</li>
          <li>C. difficile-associated diarrhea</li>
          <li>Ototoxicity (rare; reversible hearing loss with high doses)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>PO tablets:</strong> May take with or without food. Taking with food may reduce GI upset</li>
          <li><strong>IV administration:</strong> Reconstitute 500 mg vial per product monograph; dilute to 1–2 mg/mL in compatible IV fluid. Infuse over 60 minutes (or as per product monograph). Do not give as IV bolus or IM</li>
          <li>Long half-life allows once-daily dosing and short courses</li>
          <li>Counsel: complete the full course even if feeling better; report palpitations, fainting, or severe diarrhea</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (symptom improvement, fever resolution)</li>
          <li>Cardiac: assess baseline cardiac risk factors; monitor for palpitations, syncope (QT prolongation concern)</li>
          <li>GI symptoms: nausea is common but monitor for severe or persistent diarrhea (C. difficile)</li>
          <li>Hepatic: monitor for signs of hepatotoxicity (jaundice, dark urine, severe abdominal pain)</li>
          <li>Allergic reactions (rash, angioedema)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Useful for atypical respiratory infections and when penicillin allergy present</li>
          <li>Be aware of QT prolongation risk: avoid in patients with cardiac history when possible or ensure monitoring capability</li>
          <li>Short course and once-daily dosing improve adherence in operational settings</li>
          <li>IV formulation available for severe infections when oral not feasible; plan for transition to oral as soon as appropriate</li>
          <li>Document indication clearly (avoid unnecessary macrolide use to preserve effectiveness and reduce resistance)</li>
          <li>If non-responsive within 48–72 hours, reassess diagnosis and consider alternate therapy or evacuation</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (azithromycin tablets): <a href="https://pdf.hres.ca/dpd_pm/00059595.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00059595.PDF</a></li>
          <li>Health Canada product monograph (azithromycin IV): <a href="https://pdf.hres.ca/dpd_pm/00017623.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00017623.PDF</a></li>
          <li>Medscape drug reference (azithromycin): <a href="https://reference.medscape.com/drug/zithromax-azithromycin-342504" target="_blank" rel="noopener">https://reference.medscape.com/drug/zithromax-azithromycin-342504</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
